J Stroke.  2021 May;23(2):289-292. 10.5853/jos.2021.00647.

Patent Foramen Ovale Closure in Old Stroke Patients: A Subgroup Analysis of the DEFENSE-PFO Trial

• Kwon H
• Lee PH
• Song JK
• Kwon SU
• Kang DW
• Kim JS

• KMID: 2516420
• DOI: http://doi.org/10.5853/jos.2021.00647

Figure

• 

  Figure 1. Kaplan-Meier estimates for patent foramen ovale (PFO) closure and primary endpoint. Event-free survival of all the patients in the PFO-closure group (red line), patients aged <60 years in the medical-treatment group (blue line), and patients aged ≥ 60 years in the medical-treatment group (green line).

Reference

References

1. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017; 377:1022–1032.

2. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017; 377:1011–1021.

3. Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017; 377:1033–1042.

4. Messé SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020; 94:876–885.

5. Köhrmann M, Schellinger PD, Tsivgoulis G, Steiner T. Patent foramen ovale: story closed? J Stroke. 2019; 21:23–30.

6. Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE- PFO trial. J Am Coll Cardiol. 2018; 71:2335–2342.

7. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984; 59:17–20.

8. Homma S, DiTullio MR, Sacco RL, Sciacca RR, Mohr JP; PICSS Investigators. Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke. 2004; 35:2145–2149.

9. Mazzucco S, Li L, Rothwell PM. Prognosis of cryptogenic stroke with patent foramen ovale at older ages and implications for trials: a population-based study and systematic review. JAMA Neurol. 2020; 77:1279–1287.

10. Gregson J, Kaptoge S, Bolton T, Pennells L, Willeit P, Burgess S, et al. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 2019; 4:163–173.

11. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001; 104:2797–2802.